Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Debate JudgeBuy
Generated at:2026-04-18 05:46:07
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-04-17
  • The bullish analyst correctly identifies the Phase III data for Foundayo as a material de-risking event, transforming the drug's commercial potential.
  • Furthermore, this news redefines the long-term revenue trajectory and justifies a higher valuation floor, rather than being fully priced in.
  • Most importantly, the technical report supports the fundamental shift with signs of selling exhaustion and new buying interest around key support.
  • Therefore, despite extreme valuation and valid risks, the news has altered the fundamental risk/reward calculus in favor of the long-term growth story.
Bear Case
  • Technical trend is damaged with price below the 60-day MA and weak ADX.
  • Valuation is unsustainable with a Forward P/E of 91.43.
  • Recent rally is hitting firm resistance near $963.
  • Massive execution, competition, and financial leverage risks are priced to perfection.
Bull Case
  • Positive Phase III data for Foundayo de-risks the drug for the massive diabetes market.
  • Data expands the total addressable market and justifies a fundamental re-rating.
  • Technicals show a higher low with bullish MACD divergence and volume accumulation.
  • Explosive profitability and cash flow can handle the company's debt.

Price Targets

Analysis Summary

Fundamental Baseline: Morgan Stanley’s recent target increase to $1,327 provides a near-term analyst anchor. Given the de-risked growth profile, a premium valuation is warranted.

  • Sentiment & News Impact: The overwhelmingly positive news supports a re-rating. The initial price bounce is likely just the start of re-evaluation.
  • Technical Levels: Key resistance is at $963, then $986 (60-day MA), then $1044 (upper chip concentration bound). Strong support is at $900-$910.

Comprehensive Target Price Range:

  • Conservative (1 Month): $960 - $1,000. Expect consolidation and a grind higher to test the declining 60-day MA.
  • Baseline (3 Months): $1,040 - $1,150. As the Foundayo launch narrative and prescription trends develop, and the Q2 earnings outlook incorporates the new data, the stock works towards analyst targets.
  • Optimistic (6 Months): $1,250 - $1,350. This assumes a smooth prescription ramp for Foundayo, no negative pipeline surprises, and the market continuing to award a premium for confirmed GLP-1 market leadership and expanded TAM. This range aligns with raised analyst price targets.

Specific Price Targets & Time Horizon:

  • 1-Month Target: $990
  • 3-Month Target: $1,095
  • 6-Month Target: $1,310

Action Strategy

Strategy Summary

1. Your Recommendation: BUY. Initiate a long position.

2. Strategic Actions:

  • Entry: Buy on a slight pullback towards the $917-$920 support zone (the 5-day & 20-day MA cluster), or on a breakout above the immediate resistance of $963.50 with volume.
  • Position Sizing: Given the high volatility (ATR ~$28), size the position smaller than usual to account for larger swings. This is a high-conviction, but high-risk, growth investment.
  • Stop-Loss: Place a hard stop-loss at $899, just below the recent swing low and the key chip distribution support. A break below this invalidates the short-term bullish structure.
  • Initial Profit Target: First target at the $986-$1000 zone (the 60-day MA and psychological resistance).
AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • The stock is significantly below its 60-day moving average ($986) after a 20%+ decline, indicating distribution, not a healthy chart. Valuation is unsustainable with a Forward P/E of 91.43 and P/B of 41.51, leaving no room for error. Foundayo's launch week prescriptions of 1,390 lagged behind a key competitor, and positive cardiovascular trial results were a priced-in regulatory requirement, not a new catalyst. Technically, there is no strong trend (ADX 13.26), and a massive supply wall exists near $963. Macro risks include intense GLP-1 competition, execution risk in scaling production, and a high Debt-to-Asset ratio (76.41%) in a rising rate environment.

Detail Preview

Alright, let's cut through the hype. I've reviewed all the data—technical, news, and fundamentals—and while the bullish chorus is loud, the cracks in the thesis are significant and growing. Let's have a real debate. First, to address the bullish analyst directly: you're pointing to the Foundayo launch data and the positive cardiovascular trial results as proof of unstoppable momentum. You're celebrating the 57% morta…

Round 2 - Bear case

  • The technicals show no trend, with the stock below its descending 60-day MA. The recent rally hit a clear resistance wall. The celebrated trial data met only the minimum requirement and was already priced in. The initial prescription launch lagged a competitor. The forward P/E of 91.43 prices in decades of flawless execution against high risks in reimbursement, production, competition, and safety. This leaves no margin for error, and the high debt ratio adds financial risk in a higher-rate environment.

Detail Preview

Alright, let's cut through the optimistic noise. My bullish friend is seeing a "valuation reset" and "accumulation" where I see a classic dead-cat bounce and a market pricing in perfection with zero margin for error. Let me dismantle this piece by piece. First, on the "valuation reset" and "new base": You call a 20%+ decline from the highs a "reset." I call it a warning shot. The technicals you're leaning on are flim…

Round 1 - Bull case

  • The recent correction was a valuation reset, not a fundamental breakdown. Since March, a base has formed. Following positive Foundayo data, the stock saw a high-volume reversal, suggesting accumulation. The bearish focus on a high Forward P/E misses that the market is pricing in a newly expanded addressable market after Foundayo's strong cardiovascular outcomes data de-risked the diabetes market. The oral launch shows demand, expanding the overall GLP-1 pie. Technically, the stock is consolidating after its decline, with a key holder cost base providing support. Lilly's high debt is strategic, supported by massive cash flow, and funds production scaling for unprecedented demand.

Detail Preview

Bullish Analyst Rebuttal: The Foundation for the Next Leg Higher is Being Laid Right Now Let's address the bear case head-on, because I believe it's focusing on the wrong metrics and missing the seismic, fundamental shift that just occurred. You're right that the chart looks damaged from the February peak. A 20% correction is significant. But calling it "distribution" ignores the critical context: this was a valuatio…

Round 2 - Bull case

  • The stock's technicals show a higher low forming after a healthy correction, with positive MACD momentum. The forward P/E reflects a fundamental re-rating after Foundayo's Phase III data de-risked the drug and expanded its TAM into diabetes, justifying multi-year growth expectations. Early prescription numbers confirm demand, and Lilly's dual GLP-1 platform grows the overall market. High debt is strategic, funding manufacturing for high-demand drugs and supported by explosive, high-margin cash flow and earnings.

Detail Preview

Round 2 Bullish Analyst Summary: Let's address this point by point, because my bearish colleague is focusing on the trees while missing the forest—a forest that's on fire with growth. On Technicals & "No Trend": You cite a weak ADX and resistance near $963. I see a different picture. The stock just underwent a 20%+ correction—a healthy valuation reset after a parabolic move. What happened next? It found a floor. The…

Round 1 - Bear case

  • The stock is significantly below its 60-day moving average ($986) after a 20%+ decline, indicating distribution, not a healthy chart. Valuation is unsustainable with a Forward P/E of 91.43 and P/B of 41.51, leaving no room for error. Foundayo's launch week prescriptions of 1,390 lagged behind a key competitor, and positive cardiovascular trial results were a priced-in regulatory requirement, not a new catalyst. Technically, there is no strong trend (ADX 13.26), and a massive supply wall exists near $963. Macro risks include intense GLP-1 competition, execution risk in scaling production, and a high Debt-to-Asset ratio (76.41%) in a rising rate environment.

Detail Preview

Alright, let's cut through the hype. I've reviewed all the data—technical, news, and fundamentals—and while the bullish chorus is loud, the cracks in the thesis are significant and growing. Let's have a real debate. First, to address the bullish analyst directly: you're pointing to the Foundayo launch data and the positive cardiovascular trial results as proof of unstoppable momentum. You're celebrating the 57% morta…

Round 1 - Bull case

  • The recent correction was a valuation reset, not a fundamental breakdown. Since March, a base has formed. Following positive Foundayo data, the stock saw a high-volume reversal, suggesting accumulation. The bearish focus on a high Forward P/E misses that the market is pricing in a newly expanded addressable market after Foundayo's strong cardiovascular outcomes data de-risked the diabetes market. The oral launch shows demand, expanding the overall GLP-1 pie. Technically, the stock is consolidating after its decline, with a key holder cost base providing support. Lilly's high debt is strategic, supported by massive cash flow, and funds production scaling for unprecedented demand.

Detail Preview

Bullish Analyst Rebuttal: The Foundation for the Next Leg Higher is Being Laid Right Now Let's address the bear case head-on, because I believe it's focusing on the wrong metrics and missing the seismic, fundamental shift that just occurred. You're right that the chart looks damaged from the February peak. A 20% correction is significant. But calling it "distribution" ignores the critical context: this was a valuatio…

Round 2 - Bear case

  • The technicals show no trend, with the stock below its descending 60-day MA. The recent rally hit a clear resistance wall. The celebrated trial data met only the minimum requirement and was already priced in. The initial prescription launch lagged a competitor. The forward P/E of 91.43 prices in decades of flawless execution against high risks in reimbursement, production, competition, and safety. This leaves no margin for error, and the high debt ratio adds financial risk in a higher-rate environment.

Detail Preview

Alright, let's cut through the optimistic noise. My bullish friend is seeing a "valuation reset" and "accumulation" where I see a classic dead-cat bounce and a market pricing in perfection with zero margin for error. Let me dismantle this piece by piece. First, on the "valuation reset" and "new base": You call a 20%+ decline from the highs a "reset." I call it a warning shot. The technicals you're leaning on are flim…

Round 2 - Bull case

  • The stock's technicals show a higher low forming after a healthy correction, with positive MACD momentum. The forward P/E reflects a fundamental re-rating after Foundayo's Phase III data de-risked the drug and expanded its TAM into diabetes, justifying multi-year growth expectations. Early prescription numbers confirm demand, and Lilly's dual GLP-1 platform grows the overall market. High debt is strategic, funding manufacturing for high-demand drugs and supported by explosive, high-margin cash flow and earnings.

Detail Preview

Round 2 Bullish Analyst Summary: Let's address this point by point, because my bearish colleague is focusing on the trees while missing the forest—a forest that's on fire with growth. On Technicals & "No Trend": You cite a weak ADX and resistance near $963. I see a different picture. The stock just underwent a 20%+ correction—a healthy valuation reset after a parabolic move. What happened next? It found a floor. The…

End of debate